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Predictors of Early Cardiac Morbidity and Mortality After
Ischemic Stroke
Jane Prosser, MBBS, FRACP; Lachlan MacGregor, MBBS, MMedSc; Kennedy R. Lees, MD, FRCP;
Hans-Christoph Diener, MD; Werner Hacke, MD, PhD; Stephen Davis, MD, FRCP (Edin) FRACP;
on behalf of the VISTA Investigators
Background and Purpose—In the first 3 months after acute ischemic stroke, 2% to 6% of patients die from cardiac causes.
This may reflect preexisting cardiac disease, cardiac dysfunction related to the acute neurohumoral and autonomic stress
response to stroke, or both. Delineation of a high-risk group could facilitate prevention strategies. We aimed to describe
the temporal profile of cardiac risk after stroke and develop a predictive model of serious cardiac adverse events
(SCAEs) using baseline variables.
Methods—We used data from the one trial in the Virtual International Stroke Trials Archive that matched prespecified
criteria. Survival analysis was used to describe the temporal profile of cardiac events after stroke. Prognostic
determinants were assessed with multivariable logistic regression, and a risk score was derived from the key predictor
variables.
Results—Of 846 ischemic stroke patients, 35 (4.1%) died from cardiac causes and 161 (19.0%) suffered at least one SCAE.
The hazard of cardiac death was highest (0.001/d) in the second week. Hazard of a first SCAE peaked at 0.02/d between
day 2 and 3. The 5 factors most predictive of SCAEs were a history of heart failure (OR 3.33 [2.28, 4.89], P0.001),
diabetes (OR 2.11 [1.39, 3.21], P0.001), baseline creatinine 115mol/L (OR 1.77 [1.16, 2.70], P0.008), severe
stroke (OR 1.98 [1.34,2.91], P0.001), and a long QTc or ventricular extrasystoles on ECG (OR 1.93 [1.31, 2.85],
P0.001). Risk of SCAEs ranged from 6.3% (no predictors) to 62.2% (4 predictors).
Conclusion—Serious cardiac events are common in the acute period after stroke. Patients at highest risk are identifiable
and may benefit from more aggressive strategies to improve survival. (Stroke. 2007;38:2295-2302.)
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Most deaths after ischemic stroke can be directly attrib-uted to the initial neurologic injury. However, approx-
imately 2 to 6% of all stroke patients die from cardiac causes
in the first 3 months after ischemic stroke.1,2 After the acute
period, cardiac risk declines but remains higher than for
age-matched controls. A recent meta-analysis estimated an
annual rate of myocardial infarction (MI) and nonstroke
vascular death in stroke patients of 2.2% and 2.1%, respec-
tively.3 Despite these relatively high risks, many patients will
not have cardiac events. An approach to identifying patients
at high risk of cardiac events is required to assess potential
preemptive strategies, including monitoring, investigation,
and treatment. Such strategies have received scant attention to
date.
Cardiac risk in acute stroke populations is likely to be
linked to the prevalence of ischemic heart disease (IHD) and
other comorbidities. More recently evidence has emerged that
cerebrogenic autonomic and neurohumoral dysregulation af-
ter stroke may contribute to cardiac morbidity and mortality,
but the relative importance of this to overall cardiovascular
risk is uncertain.4
The aims of this study were first to describe the temporal
profile of cardiac mortality and morbidity within the first 3
months after stroke to determine the magnitude and time
course of the risk. Secondly we sought to identify patient
characteristics associated with an increased risk of cardiac
events during this period using simple demographic and
clinical variables available at the time of admission. We
aimed to use these predictive characteristics to derive a
simple score which could be used in a clinical setting to
stratify patients according to risk.
Materials and Methods
Subjects
The Virtual International Stroke Trials Archive (VISTA) is a
collaborative venture undertaking the collation and standardization
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of data from multiple clinical trials (21 as of July 2006) in an
academic database.5 VISTA aims to facilitate analysis of the natural
history of subgroups of stroke patients with the ultimate aim of
improving clinical trial design. We searched VISTA for any trials
which met the following prespecified criteria: (1) comprehensive
data on patient demographics, history, and baseline physiology, (2)
quantitative and qualitative ECG data at baseline,(3) documentation
of cardiac adverse events (including death), and (4) complete follow-
up. Only 1 trial (conducted in Europe and North America in 1996 to
1997) fulfilled these criteria.6 We used patients from the placebo
group only (n846), because of the potential cardiac effects of the
study drug.
Inclusion criteria were a clinical diagnosis of ischemic stroke
(supported by CT brain scan), stroke severity measured by the
European Stroke Scale (ESS) of 70 at baseline (range 0 to 100, the
lower the score, the worse the neurologic deficit),7 and commence-
ment of drug/placebo within 8 hours of stroke onset. Significant
relevant exclusions included serious ventricular arrhythmia at base-
line, 2nd/3rd degree atrioventricular block, (uncorrected) baseline QT
interval 450ms, acute or uncompensated heart failure, or acute
myocardial infarction within the preceding 6 weeks. All patients
were followed until death or the end of week 12.
Detailed demographic and historical information was collected at
enrolment, including medication use and preexisting conditions
(including diabetes, hypertension, hyperlipidemia, congestive heart
failure (CHF), ischemic heart disease (IHD), previous acute myo-
cardial infarction (AMI), and previous stroke or transient ischemic
attack). Designation of comorbidities was at the discretion of local
investigators. Baseline clinical measures included blood pressure,
heart rate, stroke severity, and routine biochemistry (including
electrolytes, total cholesterol, and creatinine). ECGs were performed
at baseline, baseline 1 hour, and day five, and were centrally
analyzed according to predetermined quantitative and qualitative
parameters (Table 2). Bazett’s formula was used to correct the QT
interval for heart rate.
The (placebo) patients received a continuous infusion of normal
saline solution of 120 mL (total) over 5 days, in addition to usual
fluids.
Definition of Outcomes
For this study we were interested in 2 outcome variables (which were
determined by local investigators).
Cardiac Mortality
Cause of death was divided into 4 categories: neurologic (deaths
attributable to stroke progression, hemorrhagic transformation, brain
edema, raised intracranial pressure, herniation), cardiac (acute myo-
cardial infarction [AMI], congestive heart failure [CH], ventricular
tachycardia/fibrillation [VT/VF] or other arrhythmia, and cardiac
arrest), pneumonia/infection and other (a heterogeneous group in-
cluding recurrent stroke, pulmonary embolism, systemic hemor-
rhage, and other miscellaneous causes).
Serious Cardiac Adverse Events
This was a composite end point defined as a nonfatal episode of
VT, VF, AMI, pulmonary edema/moderate-severe cardiac failure,
or cardiac death, as defined above (to include all the patients who
died from cardiac causes). For the purposes of survival analysis,
the time to the first event was analyzed if a patient experienced
more than one.
Statistical Analysis
Statistical analysis was performed with Stata 8.0 (Stata Corp).
Survival analysis techniques were used to model time to death for
each cause of death. All patients who did not die were followed-up
for the entire 12-week study period. Mortality from each cause was
compared using a competing risk ‘marginal probability’8 model and
the data represented graphically in terms of the hazard function. A
marginal probability approach was used, given that death from one
cause could not be presumed independent of factors that were also
prognostic of death from other causes. However, results and conclu-
sions were similar when the data were analyzed using either a
conditional probability or Kaplan–Meier function ie, where patients
dying from other causes were treated as ‘censored’.
Definition of Predictor Variables
To explore factors associated with nonfatal and fatal cardiac events,
each patient was allocated a binary code for ‘serious cardiac adverse
event’ (SCAE, if they experienced a serious cardiac adverse event at
any time during the study period). The data were analyzed using a
multivariable binary logistic regression model. We elected to model
events as a binary rather than time-to-event measure, for 2 reasons:
(1) because of the potential difficulty of handling competing risks in
the context of Cox regression, as described above, and (2) to simplify
the development of a risk score to identify high- and low-risk
patients.
Initial exploratory analysis was performed to check modeling
assumptions and select variables for a multivariable model. Only
factors (demographic, historic, and clinical) which have been dem-
onstrated to affect cardiac or stroke outcomes (or could reasonably
be expected to, based on current knowledge) were tested, to limit the
likelihood of chance associations. The factors included age, sex,
preexisting comorbidities, stroke severity, affected hemisphere,
baseline systolic blood pressure, creatinine, total cholesterol, base-
line ECG parameters, and treatment at the time of enrolment with
beta blockers or lipid lowering agents (Table 2).
Cardiac risk appeared to increase above age 75, but remained
constant below that. Hence, age was dichotomized at 75 for the
purpose of subsequent analysis. Baseline systolic blood pressure
(sBP) was also dichotomized at 110 mm Hg, as lower values were
associated with progressively greater risk but higher values were not.
Stroke severity (ESS) was examined as a continuous variable for the
initial regression analysis as risk of SCAEs appeared to increase
progressively over the range of ESS values. Plasma creatinine and
QTc interval were dichotomised about conventionally accepted
upper limits of the normal range for each.
The risk of a first SCAE was determined in relation to each
variable by univariate logistic regression. Variables with a probabil-
ity value 0.2 were included in a multivariable regression model
using forward and backward stepwise selection. Modeling assump-
tions and fit were checked and found to be adequate. Associations
are presented as odds ratios (ORs) with 95% confidence intervals.
The variables found to be most highly predictive of SCAEs were
then incorporated into a risk score. Patients were allocated 1 point for
each predictor variable present, the overall predictive score being the
sum. The test performance of the risk score to predict SCAEs and
cardiac death was summarized in terms of sensitivity and specificity.
Results
Patient Characteristics
The 846 patients were largely caucasian. Despite the cardiac
exclusion criteria, many patients had preexisting cardiac
comorbidities. 180 (21.3%) were dead at 12 weeks (Table 1).
TABLE 1. Patient Characteristics
n/846 %
Male 414 48.9
Caucasian 774 91.5
Age in years (median, range) 73 (22, 96)
Right handed 801 95.8
Right hemisphere stroke 434 51.3
ESS score (median, range) 42 (8,76)
Dead at day 84 180 21.3
Atrial fibrillation 267 31.5
Ischemic heart disease 388 44.7
Congestive heart failure 250 28.5
Diabetes mellitus 195 23.1
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Temporal Profile of Cardiac Mortality
and Morbidity
Cardiac Death
Neurologic deaths (79/180, 43.9% of all deaths) predomi-
nated overall and were clustered in the first 2 weeks (Figure
1). However, cardiac deaths made up the second largest group
(35/180, 19.4% of all deaths), with deaths from pneumonia/
infection third (29/180, 16.1%), and other miscellaneous
causes making up the last group (37/180, 20.6%).
The temporal profile of the hazard of cardiac death in
relationship to the other causes of death is shown in Figure
2a. The rate of cardiac deaths was maximal around day 14. At
that time, the hazard was 0.001 (ie, 1/1000 patients per day).
Serious Cardiac Adverse Events
161 patients (19.0%) experienced at least one SCAE. This
group comprised 7 cardiac deaths not preceded by a nonfatal
SCAE and 154 nonfatal SCAEs. Of these 154 patients, 28
subsequently died from a cardiac cause. Most SCAEs (128/
161, 79.5%) occurred in patients with a history of IHD and/or
CHF. The rate of first SCAEs peaked between day 2 and 3
(Figure 2b). At that time the hazard of a first SCAE was 0.02
(20/1000 patients per day), a rate 20 times higher than the
peak rate of cardiac death. Thereafter the rate of first events
declined.
Twelve-week mortality in the SCAE group was 74/161
(46.0%), compared with 21.3% mortality overall. In the
SCAE group (apart from the 35 who died from cardiac
causes), 18 died from neurologic causes and 20 from other
causes.
Predictive Model
As the variables which predict cardiac death should be similar
to those that predict SCAEs, we chose to build a predictive
model based on the latter because of a larger n (161 versus
35), enabling the fitting of a multivariable model, and
reduced dependence on potentially erroneous cause-of-death
coding. The unadjusted ORs for each predictor variable are
presented in Table 2. Increasing serum cholesterol was associ-
ated with a reduced risk of SCAEs. Given lack of biological
plausibility for this finding, and the possibility of confounding
by an unmeasured variable, we chose not to include it in the
multivariable model.
The 9 variables in the final model included age 75 years,
preexisting diabetes, CHF and hypertension, increasing
stroke severity, baseline creatinine 115mol/L, baseline
systolic BP 110 mm Hg, prolonged baseline QTc (450ms
for males, 470ms for females), and presence of ventricular
premature beats on baseline ECG. An ROC curve derived
directly from the 9 variable logistic regression equation is
shown in Figure 3a. Atrial fibrillation, prior stroke, and IHD
were significant univariate predictors of SCAEs, as were
ECG parameters of increasing heart rate, prolonged QRS, and
left ventricular hypertrophy, but they failed to add any
additional explanatory power to the predictive model. Sex,
affected hemisphere, treatment with lipid lowering agents and
beta blockers at the time of stroke, and other ECG parameters
were not predictive.
In an exploratory analysis, we also tested the influence of
hemispheric lateralization on the baseline ECG parameters.
Prolonged QTc interval was the only ECG parameter associ-
ated with any hemispheric lateralization. Prolonged QTc
interval was associated with left hemisphere stroke (OR 1.58
[1.14, 2.17] P0.005), independent of age, sex, and history
of IHD or CHF.
Risk Score for Prediction of SCAEs
To devise a simple risk score for prediction of cardiac events,
we needed to refine the predictive model down to a handful
of key variables, allocate a score for each, and assess test
performance with sensitivity and specificity. For simplicity,
the 2 ECG parameters were collapsed to a single category
(‘high risk ECG’prolonged QTc or presence of VPBs). As
the ESS is no longer in widespread use, stroke severity was
Figure 1. Frequency distribution of num-
bers of deaths and cause of death per
week from stroke onset; weeks 7 to 12
have been compressed because of low
absolute numbers.
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simply dichotomised about the median ESS score, dividing
the cohort arbitrarily into ‘moderate’ and ‘severe’ strokes
(mild strokes (ESS 70) were excluded at the outset).
We then repeated the multivariable analysis but restricted
the final model (by backward stepwise selection) to variables
with adjusted probability values of 0.01. The 5 remaining
key predictor variables were CHF (OR 3.33 [2.28, 4.89]
P0.001), creatinine 115mol/L (OR 1.77 [1.16, 2.70]
P0.008), diabetes (OR 2.11 [1.39, 3.21] P0.001), severe
stroke/ESS 42 (OR 1.98 [1.34, 2.91] P0.001), and a high
risk ECG (OR 1.93 [1.31, 2.85] P0.001). Each factor was
allocated a value of 0 (absent) or 1(present), giving each
patient a total cardiac risk score between 0 and 5.
Table 3 shows the risk of SCAE and cardiac death stratified
according to the score. Risk of at least 1 SCAE ranged from
6.3% (no predictors) to 62.2% (4 predictors). Risk of cardiac
death ranged from 0% (no predictors) to 18.9% (4 predictors).
Sensitivity and specificity data are summarized in ROC
curves (Figure 3, b and c). The area under the ROC curve
(AUC) for the simplified 5 variable model was 0.73 for
prediction of at least 1 SCAE and 0.79 for prediction of
cardiac death, compared with 0.76 for the ROC curve derived
directly from the full model. This indicates very similar
predictive power despite considerable simplification of the
model. At higher cutoffs, the score was very specific but not
sensitive. For example, a score of 3 predicted at least 1
Figure 2. a, Hazard (or hazard rate) per day
(marginal probability approach) for each cause
of death category. The hazard here corre-
sponds to the observed instantaneous rate of
death, from each cause, at any given time. b,
Hazard (or hazard rate) per day (marginal prob-
ability approach) for first serious cardiac
adverse event (SCAE).
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SCAE with a specificity of 86.0% and sensitivity of 44.1%,
and cardiac death with a specificity of 82.0% and sensitivity
of 57.1%.
Discussion
This is the first large scale study to examine the temporal
profile and predictive factors for cardiac mortality and mor-
bidity in the acute phase after ischemic stroke. The main
points that emerge from our study are that serious cardiac
adverse events are common and begin to occur very early
after stroke onset. Furthermore, cardiac risk can be stratified
with a 5 point risk score derived from simple clinical and
demographic variables available at the time of admission.
We found that cardiac mortality is the second commonest
cause of death in this acute stroke population, second only to
neurologic deaths as a direct result of the incident stroke. The
cardiac death rate is higher in the first 4 weeks after stroke,
then gradually declines. Most cardiac deaths were preceded
by at least 1 nonfatal SCAE, which are very common, with a
peak in the rate of first SCAE between day 2 and day 3. This
temporal peak may reflect the physiological consequences of
an acute stress response. It is consistent with published
studies of biomarkers of the acute stress response, such as
elevation of serum catecholamines, pathological elevation of
nocturnal blood pressure, and cardiac enzymes.9,10 We cannot
however rule out that some of the cardiac events were
iatrogenic, or sequelae of the (cardiac) cause of the incident
stroke, or chance occurrences in patients with established
heart disease. The occurrence of an SCAE was nonetheless a
poor overall prognostic indicator, with a case fatality rate in
these patients more than twice as high as the general study
population (46% versus 21%).
None of the variables found to be predictive of SCAEs in
the final model were unexpected. Both diabetes and elevated
creatinine have been shown to predict recurrent coronary
events and stroke in populations with established IHD.11
Regarding stroke severity, patients with preexisting heart
disease (in particular, atrial fibrillation) have been shown to
have larger, more severe strokes.12 Severe strokes are also
associated with a more pronounced inflammatory and meta-
bolic stress response, with potentially more severe cardiac
and autonomic derangement.13
It is not surprising that the prevalence of preexisting
cardiac disease in acute stroke patients influences the risk of
cardiac events. Typically the prevalence of symptomatic IHD
in acute stroke studies is 20% to 30%.2 Asymptomatic IHD is
also common, with small studies suggesting that up to 40% of
stroke patients without overt IHD may have evidence of silent
myocardial ischemia.14 A history of ischemic heart disease
and heart failure were strong univariate predictor of SCAEs,
but IHD failed to independently predict SCAEs in the
multivariable model (an effect partially explained by some
correlation between CHF and IHD). This suggests that in the
acute stroke setting left ventricular dysfunction is a critical
determinant of early cardiac risk. It is also possible that the
burden of risk from IHD is underestimated if only patients
with symptomatic IHD are considered. The lack of effect of
atrial fibrillation in the multivariable model was almost
entirely explained by correlation with CHF.
Figure 3. ROC curves. a, ROC curve for prediction of SCAEs
derived from the full 9 variable logistic regression model. AUC
0.76 [0.71 to 0.80]. b, ROC curve for prediction of SCAEs
derived from the simplified 5 variable risk score; score cut
points are marked on the curve. AUC 0.73 [0.68 to 0.77]. c,
ROC curve for prediction of cardiac death derived from the sim-
plified 5 variable risk score; score cut points are marked on the
curve. AUC 0.79 [0.73 to 0.85].
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Early hypertension (sBP 220 mm Hg) and hypotension
(sBP 150 mm Hg) have been identified as predictors of
death within 90 days in previous studies of acute ischemic
stroke.15 We found a history of treated hypertension and low
baseline sBP (110 mm Hg) predisposed to SCAEs, but
there was no relationship between baseline elevated sBP and
SCAEs. The effect of acute hypotension on all-cause mortal-
ity has been suggested to reflect impaired cerebral autoregu-
lation and consequent poor perfusion of the ischemic brain.15
We propose that at least part of the relationship between early
hypotension and mortality is explained by its association with
cardiac adverse events, and may reflect underlying left
ventricular dysfunction.
The ECG variables most highly predictive of SCAEs were
a prolonged QTc and presence of VPBs on baseline ECG.
Both VPBs and prolonged QTc are potential substrates for
lethal ventricular arrhythmias. QTc prolongation (measured
12 months after stroke) has been shown to predict cardiac
death in stroke survivors16 and correlates with left ventricular
mass index and cardiac disease burden.17 QTc interval may
also be influenced by changes in autonomic tone brought
about by cerebral infarction. We found a relationship between
QTc prolongation and left hemisphere infarction, consistent
with previous evidence linking left insular damage with
increased basal sympathetic tone.18 There was no evidence of
lateralized hemispheric influence on the occurrence of
TABLE 2. Predictors of SCAEs
Covariate
Prev (%) or
mean, SD
Univariate Analysis Multivariable Analysis (n800)
OR 95%CI P OR 95%CI P
Demographic variables
Age 75 years 41.5 1.61 1.14, 2.27 0.007 1.51 1.02, 2.25 0.040
Male sex 48.9 1.14 0.81, 1.60 0.461
Preexisting comorbidities
Diabetes 23.1 1.95 1.34, 2.84 0.001 2.13 1.39, 3.27 0.001
CHF 28.5 3.77 2.64, 5.38 0.001 3.07 2.08, 4.53 0.001
Hypertension 63.5 1.74 1.19, 2.55 0.004 1.60 1.04, 2.46 0.033
IHD 44.7 2.33 1.64, 3.32 0.001
Prior stroke 35.9 1.48 1.05, 2.10 0.023
Atrial fibrillation 31.5 1.97 1.38, 2.80 0.001
Stroke characteristics
Stroke severity 42.2, 16.8 1.19 1.07, 1.32* 0.001 1.16 1.03,1.30* 0.014
Left hemisphere (vs right) 48.7 1.12 0.79, 1.57 0.529
Physiologic parameters
Sys BP 110mmHg 3.3 2.88 1.32, 6.29 0.008 3.22 1.31, 7.95 0.011
Creatinine 115 mol/L 21.3 2.07 1.40, 3.07 0.001 1.67 1.09, 2.57 0.019
Cholesterol, mmol/L 5.5, 1.3 0.79 0.69, 0.91 0.001
Baseline ECG characteristics
Heart rate, bpm 81.2, 17.8 1.14 1.04, 1.25† 0.005
PR duration, ms 173.7, 38.5 1.01 0.96, 1.07‡ 0.613
QRS duration, ms 94.9, 24.1 1.14 1.06, 1.21‡ 0.001
QT duration, ms 377.1, 45.4 1.00 0.97, 1.04‡ 0.24
Long QTc duration§ 23.5 1.88 1.29, 2.73 0.001 1.64 1.07,2.51 0.023
L bundle branch block 6.0 1.85 0.99, 3.47 0.055
R bundle branch block 7.2 1.29 0.69, 2.41 0.419
Atrial fibrillation 22.8 1.41 0.95, 2.08 0.085
Ventricular premature beats 6.3 3.06 1.71, 5.47 0.001 3.05 1.60, 5.81 0.001
Supraventricular premature
beats
3.2 1.22 0.49, 3.08 0.668
Abnormal repolarization 4.4 0.99 0.43, 2.30 0.986
Left ventricular hypertrophy 13.8 1.52 1.02, 2.26 0.038
Old myocardial infarction 16.1 1.40 0.90, 2.18 0.133
Medications at baseline
Beta blockers 15.0 0.82 0.50, 1.36 0.438
Lipid lowering agents 4.9 0.87 0.38, 2.00 0.744
*per 10 units decrease; †per 10 bpm; ‡per 10 ms; §450 ms for males, 470 ms for females.
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SCAEs, though we could not examine insular involvement
directly. It has been suggested that stroke populations with
IHD might be protected from the effect of (left) insular
cortical ischemia because of ‘ischemic preconditioning’ of
the heart or concomitant administration of cardioprotective
drugs.4
We acknowledge some potential limitations of our data and
its interpretation. We had no data on smoking status or
baseline serum glucose and cannot assess their contributions
as predictors or potential confounders. Stroke etiological
subtype was also unavailable, and has been suggested as a
predictor of cardiac outcomes after stroke by inference.19
Definition and ascertainment of some predictor variables
(specifically comorbidities) were left to the discretion of local
investigators. Similarly, determination of outcomes for the
current study (cardiac death and SCAEs) was based on local
investigator opinion, and was not subject to review by an
independent Endpoints Committee. Classification of cause of
death after stroke is important but subject to great variability
between investigators.20 We anticipated this problem and
built the multivariable model principally around the nonfatal
SCAEs. However, inconsistencies in the measurement of
these variables may have introduced bias.
As the model has been developed from a clinical trial
population, it needs validation in a population-based cohort
before it is incorporated into clinical practice. Our data may
underestimate the risk of cardiac events, as in an unselected
stroke population the underlying prevalence of heart disease
and other comorbidities may be much higher. It is also
probable that our risk model could be refined further. Short-
term cardiac risk might be more directly assessed by mea-
sures of cardiac function in addition to the predictors we have
identified. Insular cortical ischemia (and manifestations of the
neurohumoral stress response such as elevated catechol-
amines and troponin) may predispose to cardiac events in
acute stroke patients. Because of the large burden of cardiac
disease in stroke patients (and as the vast majority of SCAEs
in our cohort occurred in patients with a history of cardiac
disease), it will be essential to assess the role of insular
cortical ischemia in unselected stroke populations.
Clinical Implications
Patients with a cardiac risk score of 4 were 10 times more
likely to suffer an SCAE than those with a score of zero
(62.2% versus 6.3%), whereas the risk of cardiac death
ranged from zero (no risk factors) to 18.9% (4 risk factors).
At higher cut points, the score was very specific but not
sensitive, so using the score to divide patients accurately into
one high and one low risk group is not possible. This provides
a continuing rationale for pursuing general cardiac risk
reduction strategies across the whole stroke population.
However, because of its high specificity, the score could
identify a patient group at very high cardiac risk who could be
selected for trials of additional targeted prevention.
One potential preemptive strategy is cardiac monitoring to
rapidly identify changes in cardiac rhythm before symptoms
arise, though some authors have also suggested trials of beta
blockers and even stellate ganglion blockade.21,22 In pub-
lished guidelines there is no consensus on which stroke
patients most need cardiac monitoring and for how long it
should be performed. The current AHA guidelines simply
recommend “cardiac monitoring during the initial evaluation
of patients with acute ischemic stroke” and the European
Stroke Initiative guidelines suggest “on-line” ECG monitor-
ing is desirable in stroke patients with a history of heart
disease.23,24 As we have demonstrated that the rate of first
SCAEs continues to rise well into the third day after stroke,
we argue that very high–risk patients should be monitored for
at least 72 hours, and that the capability to provide continuous
physiological monitoring should be offered in all stroke units.
Acknowledgments
We acknowledge the trial groups that have contributed data to
VISTA, and we thank the VISTA Steering Committee for providing
access to the data. VISTA rules normally preclude use or identifi-
cation of a single study, but in this case permission from the principal
investigator was granted. Myzoon Ali from the VISTA Coordinating
Centre in Glasgow provided assistance with raw data transfer and
interpretation. Professor John Carlin (University of Melbourne)
provided valuable statistical advice.
Sources of Funding
H.-C.D. has received financial support for research projects from
AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis,
Janssen Cilag, and Sanofi-Aventis. The Department of Neurology at
the University Duisburg-Essen received research grants from the
German Research Council (DFG), the German Ministy of Education
and Research (BMBF), the European Union, the Bertelsmann Foun-
dation, and the Heinz-Nixdorf Foundation.
Disclosures
C.D. has received honoraria for participation in clinical trials,
contribution to advisory boards or oral presentations from Abbott,
AstraZeneca, Bayer Vital, Boehringer Ingelheim, D-Pharm, Frese-
nius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-
Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Ser-
vier, Solvay, Wyeth, and Yamaguchi. W.H. has received research
support from Boehringer Ingelheim, Lilly, Sanofi-Aventis, and
Centocor. He has provided advice or worked on advisory boards for
Paion, Boehringer Ingelheim, and Sanofi-Aventis. S.D. is on the
steering committees for the FAST/Factor 7 in Intracerebral Hemor-
rhage (Novo Nordisk), and SAINT (AstraZeneca) trials. He has
provided advice or given lectures on behalf of Sanofi-Aventis, BMS,
Pfizer, Servier, and Boehringer Ingelheim.
References
1. Silver FL, Norris JW, Lewis AJ, Hachinski VC. Early mortality following
stroke: a prospective review. Stroke. 1984;15:492–496.
2. Adams RJ, Chimowitz MI, Alpert JS, Awad IA, Cerqueria MD, Fayad P,
Taubert KA. Coronary risk evaluation in patients with transient ischemic
attack and ischemic stroke: a scientific statement for healthcare profes-
TABLE 3. Twelve-Week Risk of a First SCAE and Cardiac
Death According to Cardiac Risk Score (n is Reduced Due to
Missing Data for Some Variables)
Cardiac Risk
Score
Patients
(n800)
SCAEs
(n152)
% Risk of
SCAE
Cardiac
Deaths
(n35)
% Risk of
Cardiac
Death
0 144 9 6.3 0 0
1 278 28 10.1 3 1.1
2 220 48 21.8 12 5.5
3 121 44 36.4 13 10.7
4 or 5 37 23 62.2 7 18.9
Prosser et al Predicting Early Cardiac Sequelae of Stroke 2301
 at GLASGOW UNIV LIB on January 19, 2012http://stroke.ahajournals.org/Downloaded from 
sionals from the Stroke Council and the Council on Clinical Cardiology
of the American Heart Association/Am Stroke Association. Stroke. 2003;
34:2310–2322.
3. Touze E, Varenne O, Chatellier G, Peyrard S, Rothwell PM, Mas JL. Risk
of myocardial infarction and vascular death after transient ischemic attack
and ischemic stroke: a systematic review and meta-analysis. Stroke.
2005;36:2748–2755.
4. Laowattana S, Zeger SL, Lima JA, Goodman SN, Wittstein IS, Oppen-
heimer SM Left insular stroke is associated with adverse cardiac outcome.
Neurology. 2006;66:477–483; discussion 463.
5. Ali M, Bath PMW, Curram J, Davis SM, Diener HC, Donnan GA, Fisher
M, Gregson BA, Grotta J, Hacke W, Hennerici MG, Hommel M, Kaste
M, Marler JR, Sacco RL, Teal P, Wahlgren NG, Warach S, Weir CJ, Lees
KR. The Virtual International Stroke Trials Archive (VISTA). Stroke.
2007;38:1905–1910.
6. Diener HC, Cortens M, Ford G, Grotta J, Hacke W, Kaste M, Koudstaal
PJ, Wessel T. Lubeluzole in acute ischemic stroke treatment: a
double-blind study with an 8-hour inclusion window comparing a 10-mg
daily dose of lubeluzole with placebo. Stroke. 2000;31:2543–2551.
7. Hantson L, De Weerdt W, De Keyser J, Diener HC, Franke C, Palm R,
Van Orshoven M, Schoonderwalt H, De Klippel N, Herroelen L. The
European Stroke Scale. Stroke. 1994;25:2215–2219.
8. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability
curves in summarizing competing risks failure time data? Stat Med.
1993;12:737–751.
9. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Prognostic
relevance of pathological sympathetic activation after acute thrombo-
embolic stroke. Neurology. 2001;57:833–838.
10. Ay H, Koroshetz WJ, Benner T, Vangel MG, Melinosky C, Arsava EM,
Ayata C, Zhu M, Schwamm LH, Sorensen AG. Neuroanatomic correlates
of stroke-related myocardial injury. Neurology. 2006;66:1325–1329.
11. Wattanakit K, Folsom AR, Chambless LE, Nieto FJ. Risk factors for
cardiovascular event recurrence in the atherosclerosis risk in communities
(ARIC) study. Am Heart J. 2005;149:606–612.
12. Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early
death and recurrent stroke and effect of heparin in 3169 patients with
acute ischemic stroke and atrial fibrillation in the international stroke trial.
Stroke. 2001;32:2333–2337.
13. Boysen G, Christensen H. Early stroke: a dynamic process. Stroke.
2001;32:2423–2425.
14. Rokey R, Rolak LA, Harati Y, Kutka N, Verani MS. Coronary artery
disease in patients with cerebrovascular disease: a prospective study. Ann
Neurol. 1984;16:50–53.
15. Stead LG, Gilmore RM, Decker WW, Weaver AL, Brown RD Jr. Initial
emergency department blood pressure as predictor of survival after acute
ischemic stroke. Neurology. 2005;65:1179–1183.
16. Wong Kea. Long Q. Tc predicts future cardiac death in stroke survivors.
Heart. 2003;89:377–381.
17. Wong KY, McSwiggan S, Kennedy NS, Wong SY, Gavin A, MacWalter
RS, Struthers AD. Spectrum of cardiac abnormalities associated with long
QT in stroke survivors. Heart. 2005;91:1306–1310.
18. Oppenheimer SM, Kedem G, Martin WM. Left-insular cortex lesions
perturb cardiac autonomic tone in humans. Clin Auton Res. 1996;6:
131–140.
19. Chimowitz MI, Poole RM, Starling MR, Schwaiger M, Gross MD.
Frequency and severity of asymptomatic coronary disease in patients with
different causes of stroke. Stroke. 1997;28:941–945.
20. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Classification of
cause of death after stroke in clinical research. Stroke. 2006;37:1521–1524.
21. Kinnander G, Viitanen M, Asplund K. Beta-adrenergic blockade after
stroke. A preliminary closed cohort study. Stroke. 1987;18:240–243.
22. Cheshire WP Jr., Saper CB. The insular cortex and cardiac response to
stroke. Neurology. 2006;66:1296–1297.
23. Adams HP Jr., Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB,
Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR,
Hademenos GJ. Guidelines for the early management of patients with
ischemic stroke: a scientific statement from the Stroke Council of the
American Stroke Association. Stroke. 2003;34:1056–1083.
24. Hacke W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K,
Leys D, Kwiecinski H, Toni P, Langhorne P, Diener C, Hennerici M,
Ferro J, Sivenius J, Gunnar N, Bath P, Olsen TS, Gugging M. European
Stroke Initiative recommendations for stroke management-update 2003.
Cerebrovasc Dis. 2003;16:311–337.
2302 Stroke August 2007
 at GLASGOW UNIV LIB on January 19, 2012http://stroke.ahajournals.org/Downloaded from 
